Agilent Technologies (NYSE:A) Now Covered by UBS Group

Equities researchers at UBS Group started coverage on shares of Agilent Technologies (NYSE:A) in a research note issued to investors on Wednesday. The brokerage set a “neutral” rating and a $165.00 price target on the medical research company’s stock. UBS Group’s price objective points to a potential upside of 14.50% from the company’s previous close.

A number of other equities research analysts have also recently commented on A. Jefferies Financial Group initiated coverage on shares of Agilent Technologies in a research note on Thursday, July 9th. They set a “hold” rating and a $135.00 price objective on the stock. Bank of America boosted their target price on shares of Agilent Technologies from $155.00 to $180.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. Barclays raised their price target on shares of Agilent Technologies from $150.00 to $175.00 and gave the company an “overweight” rating in a research report on Thursday, August 27th. Morgan Stanley upped their price objective on shares of Agilent Technologies from $160.00 to $175.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Finally, JPMorgan Chase & Co. raised their target price on Agilent Technologies from $180.00 to $190.00 and gave the company an “overweight” rating in a research report on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.33.

Agilent Technologies Stock Performance

A traded down $2.75 during midday trading on Wednesday, hitting $144.10. 90,060 shares of the company were exchanged, compared to its average volume of 2,237,644. The company’s 50 day simple moving average is $142.90 and its 200 day simple moving average is $128.22. The firm has a market capitalization of $40.63 billion, a price-to-earnings ratio of 28.36, a price-to-earnings-growth ratio of 2.30 and a beta of 1.24. Agilent Technologies has a 1-year low of $108.35 and a 1-year high of $163.75. The company has a current ratio of 2.05, a quick ratio of 1.56 and a debt-to-equity ratio of 0.50.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 26th. The medical research company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.13. The firm had revenue of $1.88 billion for the quarter, compared to the consensus estimate of $1.84 billion. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%.The company’s revenue was up 8.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.37 earnings per share. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, sell-side analysts predict that Agilent Technologies will post 6.2 earnings per share for the current year.

Hedge Funds Weigh In On Agilent Technologies

A number of hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System lifted its position in shares of Agilent Technologies by 12,343.3% in the second quarter. California State Teachers Retirement System now owns 54,577,058 shares of the medical research company’s stock valued at $7,249,471,000 after acquiring an additional 54,138,451 shares in the last quarter. Norges Bank purchased a new stake in Agilent Technologies during the 4th quarter valued at about $549,158,000. Bank of New York Mellon Corp increased its holdings in shares of Agilent Technologies by 87.4% in the second quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock valued at $695,227,000 after purchasing an additional 2,440,360 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Agilent Technologies in the 2nd quarter worth $260,101,000. Finally, AQR Capital Management LLC raised its stake in Agilent Technologies by 424.1% during the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock worth $240,956,000 after purchasing an additional 1,652,244 shares during the period. Institutional investors and hedge funds own 87.41% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc is a global provider of laboratory instruments, software, services and consumables used in scientific research, diagnostics and industrial testing. The company’s products support the analysis of chemical and biological substances, including liquid chromatography, gas chromatography, mass spectrometry, spectroscopy, automation and related laboratory systems.

Agilent serves customers in pharmaceutical and biotechnology research, chemical and energy production, food and environmental testing, academia, government laboratories and clinical research.